Biotechnology

A grant was issued to market the treatment of bone cancer

A grant was awarded to study the feasibility of bringing to market a new therapy for the treatment of osteosarcoma that promotes bone regeneration with fewer side effects.

The European Research Council has awarded a Proof of Concept grant to Professor Cristina Canal of the Department of Materials Science and Engineering at the Technical University of Catalonia (UPC), who aims to bridge the gap between frontier research and the market. The news became known yesterday (September 22).

Osteosarcoma is a rare disease – accounting for less than 0.2% of all cancers diagnosed – mainly affecting children and teenagers. It accounts for 2% of all cancers diagnosed in children aged 0 to 14 years and 3% of cases diagnosed in adolescents aged 15 to 19 years.

Survival of patients

Improving the survival rate of patients with osteosarcoma is one of the challenges facing the medical and scientific community, as the survival rate of patients with metastatic tumors is 30%.

The standard therapy for osteosarcoma is to remove the entire tumor with negative margins, that is, to resect areas of bone larger than the tumor itself to ensure that no cancer cells remain at the edge of the removed tissue.

Canal will use the grant to support the development of a new bone cancer therapy that avoids the side effects of traditional treatments such as chemotherapy and promotes bone regeneration once the tumor has been surgically removed.

Regeneration of bone tissue

The TRANSFORMER project (which stands for “Transforming Bone Cancer Therapy Using Composite Biomaterials Encapsulating Plasma-Generated RONS”) will develop a product that for the first time combines biomaterials for bone regeneration with an innovative therapy based on plasma gas-treated hydrogels that cause cancer cell death .

Canal said: “We want our technology to reach the market so that this therapy can one day benefit patients.

“The grant will support the development of this new technology by preparing it for clinical development, as well as studying the viability of the product and developing a business plan to attract investors.”

Innovative program

Proof of Concept funding aims to facilitate the exploration of the innovative and commercial potential of ERC-funded research. These €150,000 grants are part of the EU’s research and innovation programme, Horizon of Europe.

Bone cancer can affect any bone, but usually develops in the long bones of the legs or arms. The main symptoms can include persistent bone pain that worsens over time and continues into the night, swelling and redness with movement, which can make it difficult to move if the affected bone is close to the joint. There may also be a noticeable lump on the bone or weakness that can lead to fractures more easily than usual.

https://www.labiotech.eu/trends-news/grant-awarded-to-bring-to-market-a-treatment-for-bone-cancer/ A grant was issued to market the treatment of bone cancer

Back to top button